Drug delivery

#Collaboration #Drug delivery #Funding #Research

12 new grants for infectious disease and antimicrobial resistance 

The Bloomsbury SET – a knowledge exchange programme led by the UK’s Royal Veterinary College (RVC) – has announced a Commercialisation Pilot of 12 new grants for projects which will develop tools to better fight infectious disease or antimicrobial resistance (AMR). Supported by more than £1 million of funding, these projects will bring together researchers and businesses… Read More

#News

#AI #Drug delivery #Life sciences #Machine learning

Replatforming R&D with the TetraScience R&D data cloud 

TetraScience resolves root cause scientific data problems with a cloud-native platform, purpose-built to benefit scientists and data scientists, who use Tetra Data for automation and ML/AI. This paid-for advertorial by TetraScience appeared in the DDW / SLAS supplement in DDW Volume 23, Issue 1 – Winter 2021/22  Technology drives the… Read More

#Exclusive Content #Sponsored Content

#Cancer research #Drug delivery #Drug development #HPV #Immunology / Virology & Vaccines

HPV vaccine proven to dramatically reduce cervical cancer 

After decades of research, the UK implemented a human papillomavirus (HPV) vaccine programme for teenage girls in 2008. Now, for the first time, a study has shown that the UK HPV vaccine programme works and will save lives, according to research funded by Cancer Research UK.  The vaccine was shown to… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Drug delivery

Collaboration creates novel approach to the advanced therapy industry 

The Cell and Gene Therapy Catapult (CGT Catapult) and Deep Science Ventures have partnered to address barriers in the ATMP industry, create new companies and deliver better patient outcomes.  Recent advances in cell and gene therapies promise potential cures to devastating diseases. However, major hurdles still need to be… Read More

#News

#Bioproduction #Drug delivery #Drug development

How can the bioprocess industry respond to cost and maintain quality? 

Listen to this article on the DDW Podcast: Grant Cameron, Director at Clydeworth Consulting, examines the benefits of process intensification and highlights the steps which will improve process productivity, reduce environmental impact and decrease the cost of therapy manufacture while maintaining product quality.  The move to… Read More

#Business & Investment #Exclusive Content #Opinion

#Biopharmaceuticals #Drug delivery #Drug development

Abcam acquires BioVision and expands kit 

Abcam has completed a $340m strategic acquisition of BioVision and doubled the footprint of its immunoassay kit R&D and manufacturing facility in Eugene, Oregon. This enhanced capacity is another component of Abcam’s growth in the US, which the company says will enable it to support the research and biopharma… Read More

#News

#Data #Drug delivery #Lab automation #Software

Connectivity and data standards – a precondition for successful digitalisation 

  This paid-for whitepaper by The SiLA (Standardization in Lab Automation) consortium appeared in DDW Volume 22, Issue 4 – Fall 2021  R&D, manufacturing and contract research laboratories across many industries are investing in efforts to digitalise their processes and operations, with the goal of achieving… Read More

#Exclusive Content #Sponsored Content

#Biopharmaceutical #Clinical trials #Drug delivery #Drug development

First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief… Read More

#News

Human liver
#Drug delivery #Drug discovery #Liver disease

FDA Fast Track designation for liver disease treatment

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US… Read More

#News #Trending News

#Biosciences #Clinical trials #Drug delivery #Drug discovery #High throughput screening #Therapeutics

Mini-library approach delivers an arsenal in drug development pipeline

Listen to this article on the DDW Podcast: Dr. Naganna Nimishetti, Chief of the Small Molecule Drug Discovery Division (SMDD) and Dr. Dun Yang, CEO/CSO of Anticancer Bioscience, a precision therapeutics company headquartered in Chengdu, China, explain how the company is identifying bioactive hits using libraries of less than… Read More

#Editor's Choice #Exclusive Content #News

#Biotherapeutics #Clinical trial #Clinical Trial Authorisation #Drug delivery #Drug development #Therapeutics

FDA Fast Track designation for Parkinson’s Disease treatment

BlueRock Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for DA01 for advanced Parkinson’s disease (PD). DA01, BlueRock’s pluripotent stem cell-derived dopaminergic neuron therapy, is under evaluation in a Phase I study. “Receiving Fast Track Designation from the FDA is an important step,… Read More

#News

#Covid-19 #Drug delivery #Drug development #Drug discovery #Research

Academic investigates role of green tea compounds in Covid-19 drugs

University academic Dr Suresh Mohankumar has carried out research with colleagues in India during his time at JSS College of Pharmacy, JSS Academy of Higher Education and Research in Ooty prior to taking up his current role at Swansea University Medical School. Findings suggest that one of the compounds in… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharmaceuticals #Drug delivery #Drug development #Pharma #Pharmaceuticals

Half of pharma believes AI can help bring new drugs to market faster

New research reveals that 50% of European and US pharmaceutical manufacturing companies know artificial intelligence (AI) can help bring new drugs to market more rapidly and securely, but 96% face challenges with using it to derive value from their data. 49% of all executives surveyed say their company has no… Read More

#News

#Assays #Drug delivery #Drug discovery #In vitro

Gentronix acquires Big Blue transgenic mutation assay models

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488… Read More

#News

#Biomarkers #Drug delivery #Drug discovery #Drug screening #High throughput screening #Webinar

Webinar: Enabling biomarker discovery and screening

Multiplex assays allow researchers to measure multiple biomarkers simultaneously, offering the advantage of harvesting more insightful data to inform better decision-making, accelerate research, and increase the probability of discovery. Enabling biomarker discovery and screening with FirePlex Multiplexed Assays features the expertise of Dr Paul Wylie. In this webinar with… Read More

#News

#Biologics / Biotechnology #Bioscience #Biotechnology #Drug delivery #Drug development #Drug discovery

Switzerland: punching above its weight as global biotech hub

Listen to this article on the DDW Podcast:   To understand Switzerland’s continued success in the biotech sector and gain personal insights, Lu Rahman spoke to Michael Altorfer (CEO of the Swiss Biotech Association), Jan Lucht (Head of Biotechnology, scienceindustries), Claude Joris (Secretary General, BioAlps), and Carole Delauney (Business Development… Read More

#Editor's Choice #Exclusive Content #Market Reports #News